logo
Plus   Neg
Share
Email

Regeneron Announces Approval Of DUPIXENT In Japan - Quick Facts

Regeneron Pharmaceuticals, Inc. (REGN) announced the Ministry of Health, Labor and Welfare in Japan has granted marketing and manufacturing authorization for DUPIXENT (dupilumab) for the treatment of atopic dermatitis in adults not adequately controlled with existing therapies. DUPIXENT is a human monoclonal antibody designed to specifically inhibit signaling of two key proteins, IL-4 and IL-13, which are believed to be important contributors of the persistent underlying inflammation in atopic dermatitis, and certain other allergic or atopic diseases.

Dupixent is being jointly developed by Regeneron and Sanofi under a global collaboration agreement, and will be commercialized in Japan by Sanofi.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Qualcomm Inc. said Monday that a Chinese court has granted the chipmaker's request for preliminary injunction against Apple Inc. in China, after finding that the tech giant has infringed on two patents held by Qualcomm. Qualcomm noted that the court has ordered an immediate ban on the import, sale and offers for Apple iPhone models in China. Japanese prosecutors have indicted Japanese automaker Nissan Motor Co. Ltd. and its former chairman Carlos Ghosn on allegations of financial misconduct. Former Nissan director Greg Kelly was also indicted. Nissan said Monday that its Ghosn and Kelly were indicted for violating the Japan Financial Instruments and Exchange Act, namely making false disclosures in annual securities reports. The Abu Dhabi National Oil Co. or ADNOC joined with IBM to pilot a blockchain-based system to integrate oil and gas production operations. The platform would track, validate and execute transactions at every stage, from the production well to the end customer. ADNOC expects the blockchain technology to reduce transaction time between its operating companies.
Follow RTT